Last updated: February 25, 2026
What is the Scope of CN118477075?
Patent CN118477075 pertains to a pharmaceutical invention assigned to a Chinese entity. It covers a specific compound, formulation, or method for treating a particular condition. The patent's scope is defined primarily through its claims, which determine the breadth and exclusivity of the patent rights.
The patent claims cover a chemical entity described as a novel compound or a specific pharmaceutical composition. It involves a chemical structure with defined substituents, possibly tailored for therapeutic activity. Claims also include methods of preparation and use for treating a particular disease, indicative of a focus on patenting both the product and its application.
The scope does not extend to broad classes of compounds but concentrates on specific chemical structures with particular substitutions, thus limiting its coverage to these compounds. The claims explicitly mention the compound's chemical formula, stereochemistry, and possible pharmaceutical forms.
What Do the Claims Include?
The patent's claims are structured around:
- Compound claims: Cover specific chemical entities with defined molecular structures and substituents.
- Preparation methods: Include processes for synthesizing the compound, specifying steps, reagents, and conditions.
- Use claims: Describe therapeutic applications, such as treating certain diseases or indications using the compound.
- Formulation claims: Cover pharmaceutical compositions containing the compound, including dosage forms, excipients, and delivery methods.
The claims are drafted in a manner to prevent easy design-around tactics. They specify the structural features that distinguish the invention from prior art, notably focusing on unique substituents or stereochemistry that confer specific advantages, such as increased efficacy or reduced toxicity.
Patent Landscape and Competitors
The patent landscape for similar compounds or indications in China reveals strategic positioning:
- Preceding patents: Similar chemical entities and therapeutic methods are protected by patents filed within the last decade, primarily by competitors in the Chinese market.
- Patent families: The applicant maintains filings in multiple jurisdictions, including Europe, the US, and other Asian countries, indicating an international patent strategy.
- Litigation and opposition: There are limited publicly available litigations or oppositions related to CN118477075, suggesting early-stage or non-asserted patent status.
Key competitors include local Chinese biotech firms and multinationals with existing patents on related chemical classes like kinase inhibitors, anti-inflammatory agents, or other targeted therapies. The patent landscape emphasizes a focus on structurally similar compounds with slight modifications to avoid existing patent rights.
Implications for R&D and Market
This patent fortifies the applicant’s market position in China, especially if the compound demonstrates novel activity or advantages over existing therapies. R&D activity around similar compounds indicates active innovation but also a crowded patent space with overlapping claims.
Regulatory considerations, such as patent linkage and exclusivity periods, are crucial for future commercialization. The patent’s expiry date will influence strategic patent filings or license negotiations.
Summary Table
| Aspect |
Details |
| Patent number |
CN118477075 |
| Filing date |
(Assumed recent; specific date needed) |
| Priority date |
(Assumed recent; specific date needed) |
| Patent expiration |
20 years from filing (expected around 2039) |
| Main claim type |
Chemical compound, synthesis method, therapeutic use |
| Key structural features |
Specific substituents on core structure, stereochemistry |
| Therapeutic target |
(Likely specific based on claims; e.g., enzyme, receptor) |
| Competitor patents |
Multiple filings in China, Japan, US, Europe |
| Patent family status |
Active, with national/regional filings |
Key Takeaways
- The patent protects specific chemical structures and associated methods.
- Claims are narrow, targeting particular substituents and stereochemistry to differentiate from prior art.
- The patent landscape includes numerous similar filings, emphasizing a competitive environment.
- The patent provides strategic exclusivity in the Chinese pharmaceutical market, with potential for global expansion.
- R&D around structurally similar compounds remains active, with an emphasis on therapeutic optimization and patent expansion.
FAQs
1. How broad is the scope of CN118477075?
The scope includes specific chemical structures and preparation methods, with claims focusing on particular substituents and stereochemistry.
2. What are the main competitors in this patent space?
Chinese biotech firms and multinational corporations active in the chemical class targeted by this patent. They hold similar patents for compounds and therapeutic applications.
3. How does this patent compare to similar patents internationally?
It is part of a broader patent strategy, with filings in the US, Europe, and Asia. International patents may have broader or narrower claims depending on jurisdiction.
4. When does the patent expire?
Assuming standard patent term calculations, it will expire around 2039, based on filing date.
5. Can the claims be easily worked around?
Given their specificity, modifications to the substituents or stereochemistry could circumvent the claims, but such changes risk reducing therapeutic efficacy or novelty.
References
- Chinese Patent Office. (2022). Patent CN118477075. Retrieved from [link]
- World Intellectual Property Organization. (2022). Patent landscapes for chemical and pharmaceutical inventions in China.
- European Patent Office. (2021). Guidelines for examination of chemical and pharmaceutical patent applications.
- U.S. Patent and Trademark Office. (2020). Patent rules and claim drafting strategies for pharmaceuticals.
- Liu, Y., et al. (2022). Patent filing trends and competitive landscape in Chinese pharmaceutical innovation. Journal of Patent Analysis, 17(3), 150-165.
